논문번호 | 129 | ||
논문제목(영문) | Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents. | ||
국내외구분 | 국외 | SCI여부 | SCI(E) |
연구책임자역할 | 공저자 | ||
주저자명 | Li YJ | ||
교신저자명 | Rha SW | ||
공동저자명 | Li YJ, Rha SW, Chen KY, Jin Z, Wang L, Ramasamy S, Poddar KL, Minami Y, Park JY, Choi CU, Oh DJ, Jeong MH; | ||
게제년월일 | 2011-09-29 | ||
ISSN | 0914-5087 | ||
Impact Factor | 2.782 | ||
학술지명 | Journal of Cardiology | ||
서지사항 | 0집 / 59권 / 1호, 페이지(22 - 29) | ||
요약초록문 (Abstract) 입력 |
Abstract: BACKGROUND: Whether low molecular weight heparin (LMWH) enoxaparin is equivalent to unfractionated heparin (UFH) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains unclear. METHODS: A total of 2397 NSTEMI patients who underwent PCI with DES received either LMWH [n=1178, subcutaneous enoxaparin 1 mg/kg, b.i.d., initiated after the patient's arrival and continued until 3-5 days after PCI plus reduced dose of UFH (50-70 U/kg) during PCI] or UFH (n=1219, 24,000U/day infusion, initiated after the patient's arrival and continued until at least 48 h after PCI). The bleeding events and clinical outcomes during in-hospital and at 8 months were compared. RESULTS: Enoxaparin group had similar incidences of cardiac death, total death, and total major adverse cardiac events (MACE) at 8 months compared with UFH group. The incidences of major and minor bleeding events were also similar between the two groups. Multivariable Cox regression analysis showed that enoxaparin group had similar incidences of cardiac death [adjusted odds ratio (OR) 1.16, 95% confidence interval (CI) 0.64-2.10, p=0.620], total death (adjusted OR 1.08, 95% CI 0.66-1.76, p=0.760), and total MACE (adjusted OR 0.94, 95% CI 0.69-1.28, p=0.692) at 8 months as compared with UFH group. CONCLUSIONS: Enoxaparin with reduced dose of UFH only during PCI as an adjunctive antithrombotic therapy in NSTEMI patients undergoing PCI with DES was safe and showed comparable 8-month clinical outcomes as compared with UFH alone. |
||
파일 |
C129.+J+Cardiol.+2012;59(1)22-29..pdf (349.2K) DATE : 2021-05-26 09:42:34 |
전라남도 장성군 남면 삼태리 산 109 나노바이오연구원 3층 306호 TEL : 061-392-6243 Fax: 061-392-6243
Copyright ⓒ 2014 Korea Cardiovascular Stent Research Institute. All right Reserved